213 related articles for article (PubMed ID: 23997816)
1. Therapeutic advances in the management of Pompe disease and other metabolic myopathies.
Angelini C; Nascimbeni AC; Semplicini C
Ther Adv Neurol Disord; 2013 Sep; 6(5):311-21. PubMed ID: 23997816
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of metabolic myopathies.
Angelini C
Biochim Biophys Acta; 2015 Apr; 1852(4):615-21. PubMed ID: 24997454
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.
Manta A; Spendiff S; Lochmüller H; Thompson R
J Neuromuscul Dis; 2021; 8(3):401-417. PubMed ID: 33720849
[TBL] [Abstract][Full Text] [Related]
4. Treatment Opportunities in Patients With Metabolic Myopathies.
Ørngreen MC; Vissing J
Curr Treat Options Neurol; 2017 Sep; 19(11):37. PubMed ID: 28932990
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Riboflavin Responsiveness in Multiple Acyl-CoA Dehydrogenase Deficiency.
Yıldız Y; Talim B; Haliloglu G; Topaloglu H; Akçören Z; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Pediatr Neurol; 2019 Oct; 99():69-75. PubMed ID: 31331668
[TBL] [Abstract][Full Text] [Related]
6. Characterization of two ETFDH mutations in a novel case of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.
Missaglia S; Tavian D; Moro L; Angelini C
Lipids Health Dis; 2018 Nov; 17(1):254. PubMed ID: 30424791
[TBL] [Abstract][Full Text] [Related]
7. Metabolic myopathies: the challenge of new treatments.
Angelini C; Semplicini C
Curr Opin Pharmacol; 2010 Jun; 10(3):338-45. PubMed ID: 20356791
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic challenges in metabolic myopathies.
Angelini C; Marozzo R; Pegoraro V; Sacconi S
Expert Rev Neurother; 2020 Dec; 20(12):1287-1298. PubMed ID: 32941087
[TBL] [Abstract][Full Text] [Related]
9. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.
Olsen RK; Olpin SE; Andresen BS; Miedzybrodzka ZH; Pourfarzam M; Merinero B; Frerman FE; Beresford MW; Dean JC; Cornelius N; Andersen O; Oldfors A; Holme E; Gregersen N; Turnbull DM; Morris AA
Brain; 2007 Aug; 130(Pt 8):2045-54. PubMed ID: 17584774
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for Pompe disease.
Angelini C; Semplicini C
Curr Neurol Neurosci Rep; 2012 Feb; 12(1):70-5. PubMed ID: 22002767
[TBL] [Abstract][Full Text] [Related]
11. New insights in the field of muscle glycogenoses.
Oldfors A; DiMauro S
Curr Opin Neurol; 2013 Oct; 26(5):544-53. PubMed ID: 23995275
[TBL] [Abstract][Full Text] [Related]
12. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
Case LE; Beckemeyer AA; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
[TBL] [Abstract][Full Text] [Related]
13. Myopathies due to enzyme deficiencies.
Cornelio F; Di Donato S
J Neurol; 1985; 232(6):329-40. PubMed ID: 2934518
[TBL] [Abstract][Full Text] [Related]
14. Novel
Fan X; Xie B; Zou J; Luo J; Qin Z; D'Gama AM; Shi J; Yi S; Yang Q; Wang J; Luo S; Chen S; Agrawal PB; Li Q; Shen Y
Mol Genet Metab Rep; 2018 Sep; 16():15-19. PubMed ID: 29988809
[TBL] [Abstract][Full Text] [Related]
15. Novel mutations in ETFDH gene in Chinese patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency.
Law LK; Tang NL; Hui J; Fung SL; Ruiter J; Wanders RJ; Fok TF; Lam CW
Clin Chim Acta; 2009 Jun; 404(2):95-9. PubMed ID: 19265687
[TBL] [Abstract][Full Text] [Related]
16. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
Raben N; Plotz P; Byrne BJ
Curr Mol Med; 2002 Mar; 2(2):145-66. PubMed ID: 11949932
[TBL] [Abstract][Full Text] [Related]
17. Multiple acyl-CoA dehydrogenation deficiency as decreased acyl-carnitine profile in serum.
Wen B; Li D; Li W; Zhao Y; Yan C
Neurol Sci; 2015 Jun; 36(6):853-9. PubMed ID: 25827849
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency.
Cornelius N; Frerman FE; Corydon TJ; Palmfeldt J; Bross P; Gregersen N; Olsen RK
Hum Mol Genet; 2012 Aug; 21(15):3435-48. PubMed ID: 22611163
[TBL] [Abstract][Full Text] [Related]
19. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
Kishnani PS; Beckemeyer AA; Mendelsohn NJ
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
[TBL] [Abstract][Full Text] [Related]
20. A Novel Truncating FLAD1 Variant, Causing Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) in an 8-Year-Old Boy.
Ryder B; Tolomeo M; Nochi Z; Colella M; Barile M; Olsen RK; Inbar-Feigenberg M
JIMD Rep; 2019; 45():37-44. PubMed ID: 30311138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
